Valter Duro Garcia

Valter Duro Garcia

Auto-generated profile, based on publicly available information

Valter Duro Garcia

Santa Casa de Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
LALuis Gustavo Modelli de Andrade
Luis Gustavo Modelli de Andrade
TSTainá Veras de Sandes-Freitas
Tainá Veras de Sandes-Freitas
LRLucio Requião-Moura
Lucio Requião-Moura
LVLaila Almeida Viana
Laila Almeida Viana
MCMarina Pontello Cristelli
Marina Pontello Cristelli
CBCovid-19-Kt Brazil
Covid-19-Kt Brazil
This analysis, using data from the Brazilian kidney transplant (KT) COVID-19 study, seeks to develop a prediction score to assist in COVID-19 risk stratification in KT recipients. In this study, 1379 patients (35 sites) were enrolled, and a machine learning approach was used to fit models in a derivation cohort. A reduced Elastic Net model was selected, and the accuracy to predict the 28-day fatality after the COVID-19 diagnosis, assessed by the area under the ROC curve (AUC-ROC), was confirmed in a validation cohort. The better calibration values were used to build the applicable ImAgeS score. The 28-day fatality rate was 17% (n = 235), which was associated with increasing age, hypertension and cardiovascular disease, higher body mass index, dyspnea, and use of mycophenolate acid or azathioprine. Higher kidney graft function, longer time of symptoms until COVID-19 diagnosis, presence of anosmia or coryza, and use of mTOR inhibitor were associated with reduced risk of death. The coefficients of the best model were used to build the predictive score, which achieved an AUC-ROC of 0.767 (95% CI 0.698–0.834) in the validation cohort. In conclusion, the easily applicable predictive model could assist health care practitioners in identifying non-hospitalized kidney transplant patients that may require more intensive monitoring. Trial registration: ClinicalTrials.gov NCT04494776.

28 June 2021 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
VGValter Duro Garcia
Valter Duro Garcia
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes

8 November 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HNHong Si Nga
Hong Si Nga
LPLilian Monteiro Pereira Palma
Lilian Monteiro Pereira Palma
MNMiguel Ernandes Neto
Miguel Ernandes Neto
IFIda Maria Maximina Fernandes-Charpiot
Ida Maria Maximina Fernandes-Charpiot
VGValter Duro Garcia
Valter Duro Garcia
LALuis Gustavo Modelli de Andrade
Luis Gustavo Modelli de Andrade
Background: Atypical Hemolytic Uremic Syndrome (aHUS) is an ultra-rare disease that potentially leads to kidney graft failure due to ongoing Thrombotic Microangiopathy (TMA). The aim was evaluating the frequency of TMA after kidney transplantation in patients with aHUS in a Brazilian cohort stratified by the use of the specific complement-inhibitor eculizumab. Methods: This was a multicenter retrospective cohort study including kidney transplant patients diagnosed with aHUS. We collected data from 118 transplant centers in Brazil concerning aHUS transplanted patients between 01/01/2007 and 12/31/2019. Patients were stratified into three groups: no use of eculizumab (No Eculizumab Group), use of eculizumab for treatment of after transplantation TMA (Therapeutic Group), and use of eculizumab for prophylaxis of aHUS recurrence (Prophylactic Group). Results: Thirty-eight patients with aHUS who received kidney transplantation were enrolled in the study. Patients’ mean age was 30 years (24–40), and the majority of participants was women (63% of cases). In the No Eculizumab Group (n = 11), there was a 91% graft loss due to the TMA. The hazard ratio of TMA graft loss was 0.07 [0.01–0.55], p = 0.012 in the eculizumab Prophylactic Group and 0.04 [0.00–0.28], p = 0.002 in the eculizumab Therapeutic Group. Conclusion: The TMA graft loss in the absence of a specific complement-inhibitor was higher among the Brazilian cohort of kidney transplant patients. This finding reinforces the need of eculizumab use for treatment of aHUS kidney transplant patients. Cost optimization analysis and the early access to C5 inhibitors are suggested, especially in low-medium income countries.

1 January 2019 in Clinics
Verified
Journal Article
Open access
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
JPJose Medina Pestana
Jose Medina Pestana
VGValter Duro Garcia
Valter Duro Garcia

5 July 2024 in Transplantation Direct
Verified
Journal Article
Open access
HJHelio Tedesco-Silva Junior
Helio Tedesco-Silva Junior
TRTeresa Raquel de Moraes Ramos
Teresa Raquel de Moraes Ramos
DCDeise De Boni Monteiro de Carvalho
Deise De Boni Monteiro de Carvalho
GFGUSTAVO FERNANDES FERREIRA
GUSTAVO FERNANDES FERREIRA
JAJoão Marcelo Medeiros de Andrade
João Marcelo Medeiros de Andrade
MFMarcelo Cunio Machado Fonseca
Marcelo Cunio Machado Fonseca
Background.: The discard of expanded criteria donor (ECD) kidneys is unacceptably high, considering the growing demand for transplantation. Using machine perfusion may reduce the discard rate, increase the number of transplants, and reduce mortality on the waiting list. Methods.: We developed a 5-y Markov model to simulate incorporating the pulsatile perfusion machine into the current government-funded healthcare system. The model compared the universal use of static cold storage for all kidneys with the selective use of machine perfusion for ECD kidneys. Real-life data were used to compose the cohort characteristics in this model. This pharmacoeconomic analysis aimed to determine the cost-effectiveness and budgetary impact of using machine perfusion to preserve ECD kidneys. Results.: Compared with the universal use of static cold storage, the use of machine perfusion for ECD kidneys was associated with an increase in the number of kidney transplants (n = 1123), a decrease in the number of patients on the waiting list (n = 815), and decrease in mortality (n = 120), with a cost difference of US dollar 4 486 009 in the period. The budget impact analysis revealed an additional cost of US dollar 4 453 749 >5 y. The budget impact analysis demonstrated a progressive reduction in costs, becoming cost-saving during the last year of the analysis. Conclusions.: This stochastic model showed that incorporating machine perfusion for ECD kidneys is most often a dominant or cost-effective technology associated with an increase in the number of transplants and a reduction in the number of patients on the waiting list, reducing mortality on the waiting list.

1 June 2020 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
NPNatália Petter Prado
Natália Petter Prado
CSCynthia Keitel da Silva
Cynthia Keitel da Silva
GMGisele Meinerz
Gisele Meinerz
RKRoger Kist
Roger Kist
VGValter Duro Garcia
Valter Duro Garcia
EKElizete Keitel
Elizete Keitel
Introduction: Kidney Donor Profile Index (KDPI) has been incorporated in the United States to improve the kidney transplant allocation system. Objectives: To evaluate deceased kidney donors’ profile using KDPI and compare to the previous United Network for Organ Sharing (UNOS) definition of expanded criteria donors (ECD) and assess the KDPI applicability to predict five-year graft survival and renal function in our sample. Methods: Retrospective cohort of 589 kidney transplants from deceased donors performed from January 2009 to May 2013 with follow-up until May 2018. Results: In 589 kidney transplants, 36.6% of donors were classified as ECD and 28.8% had KDPI ≥ 85%. Mean KDPI was 63.1 (95%CI: 60.8-65.3). There was an overlap of standard and ECD in KDPI between 60 and 95 and a significantly lower death-censored graft survival in KDPI ≥ 85% (78.6%); KDPI 0-20: 89.8%, KDPI 21-59: 91.6%, and KDPI 60-84: 83.0%; p = 0.006. The AUC-ROC was 0.577 (95%CI: 0.514-0.641; p = 0.027). Renal function at 5 years was significantly lower according to the incremental KDPI (p < 0.002). KDPI (HR 1.011; 95%CI 1.001-1.020; p = 0.008), donor-specific antibodies (HR 2.77; 95%CI 1.69-4.54; p < 0.001), acute rejection episode (HR 1.73; 95%CI 1.04-2.86; p = 0.034) were independent and significant risk factors for death-censored graft loss at 5 years. Conclusion: In our study, 36.6% were classified as ECD and 28.8% had KDPI ≥ 85%. KDPI score showed a moderate power to predict graft survival at 5 years. Renal function was significantly lower in patients with higher KDPI.